CVI Conference
Hyatt Regency Denver 650 15th St, Denver, COCSI Activities Exhibit Booth Non-CME Lunch Symposium Fellows Boot Camp Participant For more information on the conference, please visit the CVI website
CSI Activities Exhibit Booth Non-CME Lunch Symposium Fellows Boot Camp Participant For more information on the conference, please visit the CVI website
CSI Activities Live Case Breakfast Symposium Wednesday, August 17 | 7:00-8:00 am | Grand Ballroom Bioskills Lab Thursday, August 18 | 6:00-7:30 pm | Marquette Room Atherectomy Workshop Participant Thursday, August 18 | 6:00-7:00 pm For more information on the conference, please visit the AMP website
ORBIT II Pivotal Trial: Prospective, multi-centered, core lab adjudicated U.S. trial. 443 patients in 49 US sites Met primary safety and efficacy endpoints in challenging, heavily stenosed lesions (84.4%: 0.5mm min lumen diameter).15
Ultimate control and trackability for guidewire access in the most challenging lesions.
• Ultra low profile and pushability for navigation inside lesions and micro channels
• HYbrid BRAiding + Coil (HYBRACOIL) construction for guidewire support and crossing
• DUal-Layer RAdiopaque (DURA) tapered tip for robustness and visibility
• Indicated for coronary and peripheral interventions.
The Sapphire II PRO is a semi-compliant balloon specifically engineered for crossing difficult lesions and tracking tortuous anatomy.
The Sapphire NC Plus combines advanced precision and engineering technologies for optimum reliability and deliverability. A truly non-compliant balloon that takes the pressure with minimal balloon growth for reliable dilatation.
For more information about product availability globally, please click below.
→APAC (Asia-Pacific)
→EMEA (Europe, Middle East, Africa)
ON has exclusive distribution rights in the following countries: Czech Republic, Slovakia, Egypt, Hong Kong, Italy, Kingdom of Saudi Arabia, Kuwait, Malaysia, Singapore, Spain, Switzerland, and United Arab Emirates; ON has non-exclusive distribution rights in Austria, France, Germany, and the Netherlands.
In November 2016, Cardiovascular Systems, Inc. (CSI) announced that Medikit, Co., Ltd. signed an exclusive distribution agreement to sell its coronary and peripheral Orbital Atherectomy Systems in Japan.
In February 2021, Cardiovascular Systems, Inc. (CSI) announced that PT. Revass Utama Medika signed an exclusive distribution agreement to sell its coronary and peripheral Orbital Atherectomy Systems in Indonesia.
Bio-Excel (Australia) Pty. Ltd.:
In March 2021, Cardiovascular Systems, Inc. (CSI) announced that Bio-Excel Co. Ltd. signed an exclusive distribution agreement to sell its coronary and peripheral Orbital Atherectomy Systems in Australia.
In April 2021, Cardiovascular Systems, Inc. (CSI) announced that RSK Medical Inc. signed an exclusive sales agent agreement to sell its coronary and peripheral Orbital Atherectomy Systems in Canada.
In August 2021, Cardiovascular Systems, Inc. (CSI) announced that CardiRad Group signed an exclusive distribution agreement to sell its coronary and peripheral Orbital Atherectomy Systems in Finland, Sweden, Norway and Denmark.
In September 2021, Cardiovascular Systems, Inc. (CSI) announced that ProCardia Medical Sp. z o. o. signed an exclusive distribution agreement to sell its coronary and peripheral Orbital Atherectomy Systems in Poland.
In August 2021, Cardiovascular Systems, Inc. (CSI) announced that Vascular Perspectives Ltd. signed an exclusive sales agent agreement to sell its coronary and peripheral Orbital Atherectomy Systems in U.K.
SISK Healthcare/Synapse Medical
In September 2021, Cardiovascular Systems, Inc. (CSI) announced that SISK Healthcare UC Trading as Synapse Medical signed an exclusive distribution agreement to sell its coronary and peripheral Orbital Atherectomy Systems in Ireland.
Last week, we presented our inaugural Education Excellence Award to Dr. Jihad Mustapha at a CSI event in connection with the Amputation Prevention Symposia held in Chicago. Dr. Mustapha has been a pioneer in preventing amputations due to critical limb ischemia (CLI) which is the worst form of peripheral arterial disease (PAD). We are honored that Dr. Mustapha worked with CSI last year to inspire and train 188 physicians as part of our industry-leading professional education program on the treatment of CLI. Here is a photo of Dr. Mustapha celebrating the award with our CEO, Scott Ward, and a panel of esteemed key opinion leaders in the field of amputation prevention at our most recent educational event.
Now Introducing
Designed to perform
Flexible nitinol body for reduced wire bias and kink resistance during coronary procedures
Designed for trackability
Stainless steel support coil provides floppy, shapeable tip for navigation in multi-vessel coronary lesions
At CSI, weare a culture of innovation.
We observe carefully, listen closely and collaborate extensively,
seeking opportunities to help interventionalists do their jobs more easily and more effectively –
all with the goal of improving patient care.